©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessGlomerulonephritis, membranoproliferative; differential diagnosis


Short information

Comprehensive differential diagnostic panel for membranoproliferative glomerulonephritis comprising 10 guideline-curated core genes and altogether 15 curated genes according to the clinical signs

Number of genes
15 Accredited laboratory test
Examined sequence length
21,9 kb (Core-/Core-canditate-Genes)
30,1 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications



Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
CD461179NM_002389.4AD, AR
CFHR1993NM_002113.3AD, AR
CFHR3993NM_021023.6AD, AR
CFI1752NM_000204.5AR, AD

Informations about the disease

Clinical Comment

Membranoproliferative or mesangiocapillary glomerulonephritis (MPGN) was primarily a (light or electron) microscopic diagnosis, which is now supplemented by integrated information from clinic, serology and genetics. MPGN I is characterized by immune complexes with poly- or monoclonal IgG antibodies; MPGN II is complement-mediated glomerulonephritis. Type II is now referred to as C3 glomerulopathy (C3GP). The onset od C3GP is characterized by micro- or macroscopic hematuria, proteinuria and progressive renal function impairment. Renal function impairment is more common in adults and the elderly. These clinical manifestations are common to all three subtypes of C3GP ("dense deposits disease" DDD; C3 glomerulonephritis, CFHR5 glomerulopathy) based on aberrant control of the alternative complement pathway and sequential deposition of C3 in the glomeruli. DDD onset is characterized by either nephrotic or acute nephritic syndrome. Hypertension may be present at onset or later. In a few cases, DDD shows drusen at the fundus oculi, and some patients may have partial lipodystrophy as in MPGN. Diseases from this group are inherited either autosomal recessively or dominantly. The molecular genetic yield is little over 20% in these very rare conditions. A negative molecular genetic result does not constitute exclusion of the clinical diagnosis.

References: https://www.ncbi.nlm.nih.gov/books/NBK1425/


  • Alias: Mesangiocapillary glomerulonephritis; MPGN
  • Allelic: Basal laminar drusen (CFH)
  • Allelic: C3 deficiency (C3)
  • Allelic: Complement factor B deficiency (CFB)
  • Allelic: Complement factor H deficiency (CFH)
  • Allelic: Fish-eye disease (LCAT)
  • Allelic: Macular degeneration, age-related, 14, reduced risk of (CFB)
  • Allelic: Macular degeneration, age-related, 4 (CFH)
  • Allelic: Macular degeneration, age-related, 9 (C3)
  • Allelic: Macular degeneration, age-related, reduced risk of (CFHR1, CFHR2, CFHR3, CFHR4)
  • Allelic: Macular degeneration, age-related, reduced risk of (CFHR3)
  • Allelic: Thrombophilia due to thrombomodulin defect (THBD)
  • C3 glomerulopathy (CFHR2, CFI)
  • Complement factor D deficiency (CFD)
  • Hemolytic uremic syndrome, atypical, susceptibility to (CFHR1, CFHR2, CFHR3, CFHR4)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 1 (CFH)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 2 (CD46)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 3 (CFI)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 4 (CFB)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 5 (C3)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 6 (THBD)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 7 (DGKE)
  • Immune-complex-mediated MPGN (CFHR2, CFI)
  • Methylmalonic aciduria and homocystinuria, cblC type (MMACHC)
  • Nephropathy due to CFHR5 deficiency (CFHR5)
  • Nephrotic syndrome, type 7 (DGKE)
  • Norum disease (LCAT)
  • Thrombotic thrombocytopenic purpura, hereditary (ADAMTS13)
Heredity, heredity patterns etc.
  • AD
  • AR
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

No text defined